secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001570562-25-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus posts record FY2024 revenue $266.3M (+32%); guides 2025 $345-355M; FDA for HA gels within 90 days
--------------------------------------------------------------------------------

- Preliminary Q4 2024 net revenue $79.0M (+30% YoY); FY2024 net revenue $266.3M (+32% YoY) at top of guidance ($260-266M).
- Expects FDA approval within 90 days for Evolysse Form and Smooth HA gels; US launch planned Q2 2025, a quarter ahead of prior timeline.
- 2025 revenue guidance $345-355M (30-33% growth); non-GAAP operating expenses $230-240M; positive non-GAAP operating income expected for full-year 2025.
- Cash and equivalents $87M as of Dec 31, 2024, up from $85M on Sep 30; >15,300 accounts purchasing Jeuveau since launch.
- Evolus Rewards enrollment grew over 40% to ~1.1M; Q4 redemptions record ~220,000, with ~60% from repeat treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056225000006/0001570562-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056225000006/eols-20250121.htm
  HTML page:      https://secwatch.observer/filing/0001570562-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer